(NASDAQ: IMRN) Immuron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.03%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.17%.
Immuron's earnings in 2024 is -$4,784,108.On average, 1 Wall Street analyst forecast IMRN's earnings for 2025 to be -$4,559,967, with the lowest IMRN earnings forecast at -$4,559,967, and the highest IMRN earnings forecast at -$4,559,967. On average, 1 Wall Street analyst forecast IMRN's earnings for 2026 to be -$6,839,950, with the lowest IMRN earnings forecast at -$6,839,950, and the highest IMRN earnings forecast at -$6,839,950.
In 2027, IMRN is forecast to generate -$2,279,983 in earnings, with the lowest earnings forecast at -$2,279,983 and the highest earnings forecast at -$2,279,983.